Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.58 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774427 | 0.96 | TYR (0.54) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL25471796 | 0.96 | TYR (0.54) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL27406814 | 0.95 | TYR (0.56) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL25471793 | 0.95 | TYR (0.56) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL29838907 | 0.93 | ITGB3 (0.56) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL17685892 | 0.93 | ITGB3 (0.56) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL25471896 | 0.93 | TYR (0.52) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL25471783 | 0.91 | HDAC8 (0.53) | TYRCTSLCTSBCTSSTACR1 | |
| SCHEMBL27406816 | 0.91 | TYR (0.50) | TYRMBTPS1CTSLCTSBCTSS | |
| SCHEMBL27406822 | 0.91 | HDAC8 (0.53) | TYRCTSLCTSBCTSSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230106081-A1 | METHODS OF TREATING PARKINSON'S DISEASE | ABBVIE INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220153765-A1 | METHODS OF TREATING PARKINSON'S DISEASE | ABBVIE INC. | 2022-05-19 | — | — | US | disclosed |
| EP-0309827-B1 | L-DOPA DERIVATIVES OR THEIR ACID ADDITION SALTS, PROCESS FOR PRODUCING SAME AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-01-02 | — | — | EP | disclosed |
| US-4966915-A | L-dopa derivatives or their acid addition salts, process for producing same and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0309827-A1 | L-Dopa derivatives or their acid addition salts, process for producing same and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153765-A1 | METHODS OF TREATING PARKINSON'S DISEASE | SNCA, PARK7, COMT | TYR 117/4885MBTPS1 3111/4885CTSL 394/4885 |
| US-20230106081-A1 | METHODS OF TREATING PARKINSON'S DISEASE | SNCA, PARK7, COMT | TYR 117/4885MBTPS1 3111/4885CTSL 394/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | TYR 277/4885MBTPS1 2784/4885CTSL 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.